The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug
Business Insider -

The decision to approve Aduhelm has raised concerns and led three advisors to resign. The agency's head is now asking for an outside investigation.

Read this story at

Loading...

Related Articles